arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

SpyGlass Pharma, Inc.

SGP
$28.17 ▼ -0.44 (-1.54%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
3 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

SpyGlass Pharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $62.5M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 41.9% ↘
FCF / Share $-15.11 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-39.87M
↓ -36.7% —
FCF / Share Free cash flow per share
$-15.11
↓ -12.5% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↓
96
Cash Quality →
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 3 years · 7 quarters